These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25374008)

  • 1. Oral vaccination of mice with Tremella fuciformis yeast-like conidium cells expressing HBsAg.
    Shin DI; Song KS; Park HS
    Biotechnol Lett; 2015 Mar; 37(3):539-44. PubMed ID: 25374008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of a bacteriophage-delivered DNA vaccine and a commercially available recombinant protein vaccine against hepatitis B.
    Clark JR; Bartley K; Jepson CD; Craik V; March JB
    FEMS Immunol Med Microbiol; 2011 Mar; 61(2):197-204. PubMed ID: 21204995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cationic transfersomes based topical genetic vaccine against hepatitis B.
    Mahor S; Rawat A; Dubey PK; Gupta PN; Khatri K; Goyal AK; Vyas SP
    Int J Pharm; 2007 Aug; 340(1-2):13-9. PubMed ID: 17446015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody responses in mice stimulated by various doses of the potato-derived major surface antigen of hepatitis B virus.
    Youm JW; Won YS; Jeon JH; Moon KB; Kim HC; Shin KS; Joung H; Kim HS
    Clin Vaccine Immunol; 2010 Dec; 17(12):2029-32. PubMed ID: 20943879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus surface antigen as delivery vector can enhance Chlamydia trachomatis MOMP multi-epitope immune response in mice.
    Zhu S; Feng Y; Rao P; Xue X; Chen S; Li W; Zhu G; Zhang L
    Appl Microbiol Biotechnol; 2014 May; 98(9):4107-17. PubMed ID: 24458565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Suppression of the antigen-specific T cell immune response by co-immunization with the HBV DNA vaccine and recombinant HBsAg].
    Du X; Wang J; Kang Y; Xiao W; Zhao G; Wang B
    Wei Sheng Wu Xue Bao; 2009 Jul; 49(7):938-42. PubMed ID: 19873759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral immunization of animals with transgenic cherry tomatillo expressing HBsAg.
    Gao Y; Ma Y; Li M; Cheng T; Li SW; Zhang J; Xia NS
    World J Gastroenterol; 2003 May; 9(5):996-1002. PubMed ID: 12717845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant Semliki Forest virus vectors encoding hepatitis B virus small surface and pre-S1 antigens induce broadly reactive neutralizing antibodies.
    Niedre-Otomere B; Bogdanova A; Skrastina D; Zajakina A; Bruvere R; Ose V; Gerlich WH; Garoff H; Pumpens P; Glebe D; Kozlovska T
    J Viral Hepat; 2012 Sep; 19(9):664-73. PubMed ID: 22863271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.
    Hong Y; Peng Y; Mi M; Xiao H; Munn DH; Wang GQ; He Y
    Vaccine; 2011 May; 29(22):3909-16. PubMed ID: 21421003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Construction of recombinant adeno-associated virus carrying hepatitis B surface antigen gene and preliminary study of the gene expression and function].
    Hu GF; Wu XB; Yu SY; Dong XY; Chen Q; Hou YD
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Jun; 23(6):553-6. PubMed ID: 12810373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal determination of hepatitis B surface antigen-specific B lymphocyte frequency in healthy high responder adults after booster vaccination.
    Sam MR; Shokrgozar MA; Shokri F
    Intervirology; 2008; 51(2):87-95. PubMed ID: 18477849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral administration of low doses of plant-based HBsAg induced antigen-specific IgAs and IgGs in mice, without increasing levels of regulatory T cells.
    Kostrzak A; Cervantes Gonzalez M; Guetard D; Nagaraju DB; Wain-Hobson S; Tepfer D; Pniewski T; Sala M
    Vaccine; 2009 Jul; 27(35):4798-807. PubMed ID: 19539581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model.
    Bourgine M; Dion S; Godon O; Guillen G; Michel ML; Aguilar JC
    Virology; 2012 Aug; 430(1):10-9. PubMed ID: 22591777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes.
    Shukla A; Katare OP; Singh B; Vyas SP
    Int J Pharm; 2010 Jan; 385(1-2):47-52. PubMed ID: 19835938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral response and genetic stability of recombinant BCG expressing hepatitis B surface antigens.
    Rezende CA; De Moraes MT; De Souza Matos DC; McIntoch D; Armoa GR
    J Virol Methods; 2005 Apr; 125(1):1-9. PubMed ID: 15737410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel nanocarrier for oral Hepatitis B vaccine.
    Dinda AK; Bhat M; Srivastava S; Kottarath SK; Prashant CK
    Vaccine; 2016 Jun; 34(27):3076-3081. PubMed ID: 27156634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral delivery of wafers made from HBsAg-expressing maize germ induces long-term immunological systemic and mucosal responses.
    Hayden CA; Fischer ME; Andrews BL; Chilton HC; Turner DD; Walker JH; Tizard IR; Howard JA
    Vaccine; 2015 Jun; 33(25):2881-6. PubMed ID: 25944300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses to hepatitis B virus surface and core antigens in mice, monkeys, and pigs after Accell particle-mediated DNA immunization.
    Fuller JT; Fuller DH; McCabe D; Haynes JR; Widera G
    Ann N Y Acad Sci; 1995 Nov; 772():282-4. PubMed ID: 8546409
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel immunogenicity of Oka varicella vaccine vector expressing hepatitis B surface antigen.
    Kamiyama T; Sato H; Takahara T; Kageyama S; Shiraki K
    J Infect Dis; 2000 Mar; 181(3):1158-61. PubMed ID: 10720546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The prospects for using the genetically engineered surface antigen of the hepatitis B virus (HBsAg) expressed by recombinant poxvirus strains as the basis for vaccines against hepatitis B].
    Zheleznova NV; Mukomolov SL; Zhebrun AB; Noskov FS; Malkova II; Shargorodskaia EP; Al'tshteĭn AD; Pliutnikova VA; Lavrent'eva IN; Ptichnikova NN
    Zh Mikrobiol Epidemiol Immunobiol; 1996; (5):49-53. PubMed ID: 9082729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.